MX347257B - Solido de gamma-carbolinas fusionadas con heterociclos substituidos. - Google Patents
Solido de gamma-carbolinas fusionadas con heterociclos substituidos.Info
- Publication number
- MX347257B MX347257B MX2014007104A MX2014007104A MX347257B MX 347257 B MX347257 B MX 347257B MX 2014007104 A MX2014007104 A MX 2014007104A MX 2014007104 A MX2014007104 A MX 2014007104A MX 347257 B MX347257 B MX 347257B
- Authority
- MX
- Mexico
- Prior art keywords
- carbolines
- substituted heterocycle
- solid
- heterocycle fused
- fused gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente invención se refiere a cristales de sal de adición de ácido toluenosulfónico de gamma-carbolinas fusionadas con heterociclos substituidos específicos, el método para hacer y usar tales cristales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3606908P | 2008-03-12 | 2008-03-12 | |
PCT/US2009/001608 WO2009114181A2 (en) | 2008-03-12 | 2009-03-12 | Substituted heterocycle fused gamma-carbolines solid |
Publications (1)
Publication Number | Publication Date |
---|---|
MX347257B true MX347257B (es) | 2017-04-20 |
Family
ID=41065729
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
MX2014007104A MX347257B (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Country Status (17)
Country | Link |
---|---|
US (4) | US8648077B2 (es) |
EP (1) | EP2262505B1 (es) |
JP (1) | JP5611846B2 (es) |
KR (2) | KR20150140418A (es) |
CN (2) | CN102046175B (es) |
AU (1) | AU2009223701B2 (es) |
CA (1) | CA2716730C (es) |
DK (1) | DK2262505T3 (es) |
ES (1) | ES2530090T3 (es) |
HK (1) | HK1152231A1 (es) |
HR (1) | HRP20141178T1 (es) |
IL (3) | IL207772A0 (es) |
MX (2) | MX2010010024A (es) |
PL (1) | PL2262505T3 (es) |
PT (1) | PT2262505E (es) |
SI (1) | SI2262505T1 (es) |
WO (1) | WO2009114181A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
KR20150140418A (ko) | 2008-03-12 | 2015-12-15 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카볼라인 고체 |
CN102105059B (zh) | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
US11053245B2 (en) | 2012-04-14 | 2021-07-06 | Intra-Cellular Therapies, Inc. | Methods |
PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
EP3666271A1 (en) * | 2013-12-03 | 2020-06-17 | Intra-Cellular Therapies, Inc. | Miscrospheres comprising a plga matrix for medical use |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3125893B1 (en) | 2014-04-04 | 2023-09-20 | Intra-Cellular Therapies, Inc. | Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors |
EP3125892A4 (en) | 2014-04-04 | 2017-12-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
EP3407888B1 (en) | 2016-01-26 | 2020-12-30 | Intra-Cellular Therapies, Inc. | Pyridopyrroloquinoxaline compounds, their compositions and uses |
EP3888656A1 (en) | 2016-03-25 | 2021-10-06 | Intra-Cellular Therapies, Inc. | Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder |
JP6997718B2 (ja) * | 2016-03-28 | 2022-01-18 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
JP2019513143A (ja) * | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規塩類および結晶 |
EP4001281A1 (en) | 2016-08-09 | 2022-05-25 | Teva Pharmaceuticals International GmbH | Solid state forms of lumateperone ditosylate salt and preparation thereof |
JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
JP2020513023A (ja) | 2017-04-10 | 2020-04-30 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ルマテペロンp−トシラートの非晶質形態および固体分散体 |
JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
CA3071119A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2020535231A (ja) * | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規な塩および結晶 |
EP3717484A4 (en) * | 2017-11-27 | 2021-08-04 | Egis Gyógyszergyár Zrt. | PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT |
CN109867674A (zh) * | 2017-12-05 | 2019-06-11 | 上海度德医药科技有限公司 | 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型 |
CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
WO2019236889A1 (en) | 2018-06-06 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
EP3801527A4 (en) * | 2018-06-08 | 2022-03-30 | Intra-Cellular Therapies, Inc. | NEW METHODS |
WO2019241278A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
CA3108304A1 (en) | 2018-06-21 | 2019-12-26 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
US11541002B2 (en) | 2018-09-07 | 2023-01-03 | Aquestive Therapeutics, Inc. | Oral film compositions and dosage forms having precise active dissolution profiles |
EP3887374A2 (en) | 2018-11-27 | 2021-10-06 | Teva Pharmaceuticals International GmbH | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
WO2020182978A1 (en) | 2019-03-13 | 2020-09-17 | Sandoz Ag | Crystalline salt of a 5-ht2a receptor antagonist |
US20210000822A1 (en) | 2019-07-07 | 2021-01-07 | Intra-Cellular Therapies, Inc. | Novel methods |
IL292487A (en) | 2019-11-01 | 2022-06-01 | Aquestive Therapeutics Inc | Compositions of medicinal meters and methods of treatment |
WO2021097247A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions and methods of treatment |
WO2021119334A1 (en) | 2019-12-11 | 2021-06-17 | Intra-Cellular Therapies, Inc. | Organic compound |
CA3208345A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
US20220347117A1 (en) | 2021-03-09 | 2022-11-03 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
CA3217549A1 (en) * | 2021-06-07 | 2022-12-15 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
US20230372336A1 (en) | 2022-05-18 | 2023-11-23 | Intra-Cellular Therapies, Inc. | Novel methods |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
US6552017B1 (en) | 1999-06-15 | 2003-04-22 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7462641B2 (en) | 2003-07-21 | 2008-12-09 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
KR20150140418A (ko) | 2008-03-12 | 2015-12-15 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카볼라인 고체 |
CN102105059B (zh) | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
US11053245B2 (en) | 2012-04-14 | 2021-07-06 | Intra-Cellular Therapies, Inc. | Methods |
PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
-
2009
- 2009-03-12 KR KR1020157034267A patent/KR20150140418A/ko not_active Application Discontinuation
- 2009-03-12 CA CA2716730A patent/CA2716730C/en active Active
- 2009-03-12 EP EP09718951.8A patent/EP2262505B1/en active Active
- 2009-03-12 US US12/922,056 patent/US8648077B2/en active Active
- 2009-03-12 CN CN200980108387.XA patent/CN102046175B/zh active Active
- 2009-03-12 MX MX2010010024A patent/MX2010010024A/es active IP Right Grant
- 2009-03-12 PT PT97189518T patent/PT2262505E/pt unknown
- 2009-03-12 ES ES09718951.8T patent/ES2530090T3/es active Active
- 2009-03-12 JP JP2010550697A patent/JP5611846B2/ja active Active
- 2009-03-12 KR KR1020107022312A patent/KR101610977B1/ko active IP Right Grant
- 2009-03-12 MX MX2014007104A patent/MX347257B/es unknown
- 2009-03-12 WO PCT/US2009/001608 patent/WO2009114181A2/en active Application Filing
- 2009-03-12 SI SI200931092T patent/SI2262505T1/sl unknown
- 2009-03-12 DK DK09718951.8T patent/DK2262505T3/en active
- 2009-03-12 CN CN201510456013.4A patent/CN105237536A/zh active Pending
- 2009-03-12 AU AU2009223701A patent/AU2009223701B2/en active Active
- 2009-03-12 PL PL09718951T patent/PL2262505T3/pl unknown
-
2010
- 2010-08-24 IL IL207772A patent/IL207772A0/en unknown
-
2011
- 2011-06-20 HK HK11106289.4A patent/HK1152231A1/xx unknown
-
2014
- 2014-02-11 US US14/177,689 patent/US9199995B2/en active Active
- 2014-12-05 HR HRP20141178AT patent/HRP20141178T1/hr unknown
-
2015
- 2015-11-30 US US14/954,845 patent/US9586960B2/en not_active Ceased
-
2018
- 2018-11-28 IL IL263338A patent/IL263338A/en unknown
-
2019
- 2019-03-06 US US16/294,607 patent/USRE48825E1/en active Active
-
2022
- 2022-01-09 IL IL289706A patent/IL289706A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347257B (es) | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. | |
MX353257B (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
EP2254944A4 (en) | COMPOSITION FOR THE FORMATION OF GELS | |
MX2012007710A (es) | Alfa-amilasas. | |
IN2009DN05670A (es) | ||
ZA201203779B (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
HK1179957A1 (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes hsl - | |
MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
MY155330A (en) | Methods for salt production | |
ZA201404327B (en) | Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof | |
MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
EA201001870A1 (ru) | Новые кристаллические формы рабепразола натрия | |
MX2011012623A (es) | Construcciones de casb7439. | |
EA201001353A1 (ru) | Гидробромид ивабрадина | |
WO2012063115A3 (en) | Process for the preparation of rosuvastatin calcium via novel amine intermediate | |
EA201190256A1 (ru) | Способ снижения уровня убиквитинилированных белков | |
IL212850A0 (en) | Novel method for the preparation of granulates of active constituents, and granulates as obtained | |
UA99198C2 (ru) | Соединения фенантренона, композиция, содержащая их, и способ лечения | |
MX2010003056A (es) | Polimorfos de valomaciclovir. |